Van Eijck

Nov 10, 2024 | biomedical-engineering-online.biomedcentral.com | Van Eijck

MethodsThis study constituted a single-center, non-randomized interventional study involving healthy volunteers equipped with the Corsano CardioWatch 287–2 during HIIT. The study consisted of a single visit per participant and took place from January 2024 till March 2024 at the Hague Tech center (The Hague, the Netherlands).

Oct 14, 2024 | academic.oup.com | Eva M. M |Amsterdam UMC |Marc G H |Van Eijck

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-associated mortality, with a 5-year survival of 13%1. Localized (that is non-metastatic) PDAC is classified as resectable, borderline resectable (BR), or locally advanced (LA), based on the extent of vascular contact2. The combination of systemic chemotherapy and surgical resection results in the best long-term survival3. Neoadjuvant and induction treatment has become the standard of care for patients with BR and LA PDAC.

Aug 7, 2023 | bmccancer.biomedcentral.com | Van Dam |van Driel |Van Eijck |de Groot

Trial designThe PREOPANC-3 trial is an international, multicenter, phase 3, RCT initiated by the Dutch Pancreatic Cancer Group (DPCG). Patients with resectable pancreatic cancer are randomized to neoadjuvant mFOLFIRINOX followed by surgery and adjuvant mFOLFIRINOX (intervention; arm 1) or to surgery and adjuvant mFOLFIRINOX (comparator; arm 2) (Fig. 1). Randomization is performed centrally in a 1:1 ratio using the minimization technique with World Health Organization (WHO) performance status (0 vs.